Drug Profile


Alternative Names: BMS-247616; S-1; Tegafur/gimeracil/oteracil potassium; Teysuno; TS-1; TS-ONE

Latest Information Update: 14 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Taiho Pharmaceutical
  • Developer Nordic Group; Shandong New age Pharmaceutical; Taiho Pharmaceutical; TTY Biopharm
  • Class Antineoplastics; Pyridines; Pyrimidinones; Small molecules; Triazines
  • Mechanism of Action Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer
  • New Molecular Entity No

Highest Development Phases

  • Marketed Biliary cancer; Breast cancer; Colorectal cancer; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Pancreatic cancer
  • Phase III Cervical cancer; Hepatocellular carcinoma; Uterine cancer
  • Phase II Oesophageal cancer; Renal cancer
  • No development reported Prostate cancer

Most Recent Events

  • 02 Jun 2017 Efficacy and adverse events data from a phase III trial in Cervical cancer presented at the 53rd Annual Meeting of American Society of Clinical Oncology (ASCO-2017)
  • 15 Jan 2017 TTY Biopharm terminates a phase I trial in Pancreatic cancer (Metastatic disease, First-line therapy) in Taiwan (PO) (NCT01946646)
  • 31 Oct 2016 Shandong New age Pharmaceutical completes a phase II trial in Oesophageal cancer (First-line therapy) in China (PO) (ChiCTR-TRC11001492)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top